Peroral peptide delivery: Peptidase inhibition as a key concept for commercial drug products.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Bioorganic & Medicinal Chemistry

• Publication date

  2017-08-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmc.2017.08.028PMID 28882504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts.

  2016cited by this paper
• Oral delivery of diabetes peptides - Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context.

  2016cited by this paper
• Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.

  2016cited by this paper
• Intestinal permeation enhancers for oral peptide delivery.

  2016cited by this paper
• ORAL PEPTIDE DELIVERY : TECHNOLOGY LANDSCAPE & CURRENT STATUS

  2015cited by this paper
• Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.

  2015cited by this paper
• Reasons for raising the maximum acceptable daily intake of EDTA and the benefits for iron fortification of foods for children 6–24 months of age

  2014cited by this paper
• The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition.

  2014cited by this paper
• Paracellular drug absorption enhancement through tight junction modulation

  2013cited by this paper
• A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial

  2012cited by this paper
• Protease Inhibitors as Cancer Chemopreventive Agents

  2012cited by this paper
• Disturbed Copper Bioavailability in Alzheimer's Disease

  2011cited by this paper
• Open‐label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects

  2010cited by this paper
• Strategies to Overcome the Enzymatic Barrier

  2009cited by this paper
• Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation.

  2009cited by this paper
• The Absorption Barrier

  2009cited by this paper
• Gastrointestinal Mucus Gel Barrier

  2009cited by this paper
• Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration.

  2007cited by this paper
• Degradation of teriparatide by gastro-intestinal proteolytic enzymes

  2006cited by this paper
• The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery

  2006cited by this paper
• Strategies to improve plasma half life time of peptide and protein drugs

  2006cited by this paper
• Evolutionary families of peptidase inhibitors.

  2004cited by this paper
• Perioperative systemic haemostatic agents.

  2004cited by this paper
• Stability of Desmopressin Loaded in Liposomes

  2003cited by this paper
• Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin.

  2003cited by this paper
• Intestinal permeation enhancers.

  2000cited by this paper
• alpha-Chymotrypsin-catalyzed degradation of desmopressin (dDAVP): influence of pH, concentration and various cyclodextrins.

  1999cited by this paper
• The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.

  1998cited by this paper
• Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

  1995cited by this paper
• Enzymatic barriers for GI peptide and protein delivery.

  1994cited by this paper
• Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin.

  1993cited by this paper
• Pharmacokinetics of 1‐deamino‐8‐d‐arginine vasopressin after various routes of administration in healthy volunteers

  1993cited by this paper
• Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat.

  1992cited by this paper
• Trypsin inhibitor levels in soy-based infant formulas and commercial soy protein isolates and concentrates

  1992cited by this paper
• Carboxypeptidase A: mechanism of zinc inhibition.

  1989cited by this paper
• Pancreatic response to long-term feeding of soy protein isolate, casein or egg white in rats.

  1987cited by this paper
• Excess zinc ions are a competitive inhibitor for carboxypeptidase A.

  1987cited by this paper
• The USDA trypsin inhibitor study. IV. The chronic effects of soy flour and soy protein isolate on the pancreas in rats after two years

  1985cited by this paper
• Lack of effects of copper gluconate supplementation.

  1985cited by this paper
• Conformation and Biological Activity of Cyclic Peptides

  1982cited by this paper
• Trypsin activity in the small intestine of rats after application of copper and zinc

  1980cited by this paper
• Carboxypeptidase A: a protein and an enzyme.

  1971cited by this paper
• Safety evaluation studies of calcium EDTA.

  1963cited by this paper
• EDTA, Ethylenediaminetetraacetic Acid

  1960cited by this paper

• Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.

  2025cites this paper
• Oxytocin Analogues for the Oral Treatment of Abdominal Pain.

  2024cites this paper
• Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers.

  2022cites this paper
• Evaluation in pig of an intestinal administration device for oral peptide delivery.

  2022cites this paper
• In silico design of peptide inhibitors of tubulin: amyloid-β as a lead compound

  2020cites this paper
• Duck Egg White-Derived Peptide VSEE (Val-Ser-Glu-Glu) Regulates bone and lipid Metabolisms by Wnt/β-catenin Signaling Pathway and Intestinal Microbiota.

  2019cites this paper
• Design of virus-mimicking polyelectrolyte complexes for enhanced oral insulin delivery.

  2019cites this paper
• Trictide, a Tricellulin-Derived Peptide to Modulate Cell Barriers and to Understand the Tricellular Organization of Tight Junctions

  2019cites this paper
• Two-level delivery systems based on CaCO3 cores for oral administration of therapeutic peptides

  2018cites this paper